Retinal changes after COVID-19, gene therapy top Euretina congress coverage
Coverage from the virtual Euretina congress included items investigating retinal changes in children who recovered from COVID-19 and vascular changes in patients with multiple sclerosis.
Check out the best-performing items from the Euretina congress below.
OCT, OCT-A show retinal changes in children recovered from COVID-19
An OCT and OCT-A study of pediatric patients recovered from COVID-19 showed that morphological and vascular structural changes in the macula and optic disc may occur, including in eyes that appear normal on biomicroscopy and fundus exam. Read more.
OCT angiography shows ability to detect subclinical vascular changes in multiple sclerosis
OCT angiography could represent a novel and helpful early biomarker for diagnosing and monitoring multiple sclerosis progression. Read more.
GT005 gene therapy shows ability to modulate complement pathway in geographic atrophy
In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed potential to regulate the complement pathway involved in the pathogenesis of geographic atrophy. Read more.
First results with THR-149 show promise in treatment of diabetic macular edema
First results with THR-149, a bicyclic peptide inhibitor that targets plasma kallikrein, showed safety and efficacy in treating patients with diabetic macular edema. Read more.
VIDEO: Proactive treatment of NPDR: What does the evidence say so far?
Should patients with nonproliferative diabetic retinopathy be treated early with prophylactic anti-VEGF therapy? Watch here.